Objective: Several studies of sex differences in lung cancer survival have been reported. However, large-size population-based studies based on long-term observation are scarce. We investigated long-term trends in sex differences in lung cancer survival using population-based cancer registry data from Osaka, Japan. Methods: We analyzed 79 330 cases from the Osaka Cancer Registry (OCR) diagnosed between 1975 and 2007. We calculated 5-year relative survival in the six periods (1975-1980, 1981-1986, 1987-1992, 1993-1997, 1998-2002 and 2003-2007). To estimate the trends in sex differences in lung cancer survival throughout the study period, we applied a multivariate excess hazard model to control for confounders. Results: The proportion of adenocarcinoma (ADC) and 5-year relative relative survival have increased for both sexes. Sex differences in lung cancer survival have widened over the period, especially in ADC and since the late 1990s. The excess hazard ratio of death within 5 years for males was 1.19 (95% CI: 1.16-1.21), adjusting for period at diagnosis, histologic type, stage, age group and treatment. Conclusion: We reported that females have better prognosis in lung cancer than males and the sex differences in lung cancer survival have become wider in Osaka, Japan. This can be partly explained by the sex differences in the proportions of histologic type and stage. Further studies considering other factors that influence sex differences in lung cancer survival are needed.
Introduction
Monitoring long-term trends in cancer survival is important to evaluate the effectiveness of treatment and cancer control activities at the population level. According to a worldwide collaborative study for cancer survival (CONCORD-2), lung cancer is one of the most lethal cancers in the world: 5-year survival, diagnosed in [2005] [2006] [2007] [2008] [2009] , is less than 20% in European and North American countries and as low as 10% in some developing countries. In contrast, lung cancer survival in Japan is reported to be as high as 30.1% (1) . Results from the latest study for population-based cancer survival in Japan showed that 5-year relative survival of lung cancer diagnosed between 2006 and 2008 is 27.0% for males and 43.2% for females (2) .
Sex is one possible factor that influences survival of cancer. Previous studies reported that females have an advantage over males in survival of most cancers (3, 4) although they have a higher risk of death from bladder cancer (3) (4) (5) (6) . In 1990, the advantage for lung cancer survival in females over males, irrespective of histologic type, was reported in USA (7) . Since then, several studies of sex differences in lung cancer survival have been reported worldwide (8) (9) (10) . Most studies have reported that female sex is an independent favorable prognostic factor for lung cancer, as well as recent period at diagnosis, never smoker, young age, early stage, receiving treatment and good performance status (scales to quantify cancer patients' general well-being and activities of daily life) in the multivariate analysis (8) (9) (10) (11) (12) . However, these studies used data based on limited groups of patients, for example, patients who had had surgery and those who had been treated at selected hospitals, which could cause selection bias in the outcome. In order to translate to cancer control activities at the population level, it is important to understand longterm trends in sex differences of lung cancer survival using population-based data. It is also essential to monitor trends in survival related prognostic factors such as histologic type. Nevertheless, those types of studies are still scarce in Japan.
We aimed to examine long-term sex differences in lung cancer survival using large-size population-based cancer registry data from Osaka, Japan. We also evaluate sex differences in lung cancer survival by histologic type and other prognostic factors.
Methods

Data sources
We obtained data from 124 521 cases of lung cancer diagnosed between 1975 and 2007 from the Osaka Cancer Registry (OCR). The OCR covered a population of 8.8 million which was monitored over 50 years, making it one of the largest population-based cancer registries in Japan. The proportion of death certificate only cases (DCO%) over the whole observed period was 19.8% and the proportion of microscopically verified cases was 72.5% for lung cancer. We excluded data that were registered as DCO from the analysis, because of the lack of information for the survival analysis. In the cases of multiple primary tumors, only a first primary was included in the survival analysis (7.2% of the total were excluded). As a consequence, we analyzed 79 330 cases, which were diagnosed from 1975 to 2007 and aged from 15 to 99 years old.
We divided years at diagnosis into six periods: 1975-1980, 1981-1986, 1987-1992, 1993-1997, 1998-2002 and 2003-2007 ) and other specified malignant neoplasm. Stage at diagnosis was classified into the following three groups based on SEER summary stage (14) . The SEER summary stage and corresponding tumor node metastasis (TNM) classification of the International Union Against Cancer (UICC) (15) are as follows: (i) localized: cancer is confined to the organ from which it originated (TNM: T1-2 N0 M0), (ii) regional metastasis: cancer metastasizes into regional lymph nodes and/or invades adjacent organs (TNM: T1-2 N1-2 M0 or T3-4 N0-2 M0), (iii) distant metastasis: cancer metastasizes to distant organs and/or lymph nodes (TNM: T any N3 M0 or T any N any M1). Age at diagnosis was classified into three categories: 15-64 years old, 65-74 years old and 75-99 years old. Information on treatment was limited to the following categories: surgery, radiotherapy and chemotherapy. These variables comprised 'done', 'not done' and 'unknown'. In our analysis, 'unknown' was treated as 'not done'. The proportions of 'unknown' in surgery/radiotherapy/chemotherapy were 3.4%/4.2%/ 3.8% for males and 3.9%/5.2%/4.6% for females, respectively.
Statistical analysis
We estimated 5-year relative survival by sex, histologic type, stage, age group and treatment (surgery, radiotherapy and chemotherapy) in each period. Relative survival was calculated as the ratio of observed survival to expected survival. The expected survival was estimated by the Ederer II method using the life tables for the general population of Japan (16) . We applied the excess hazard model, which is a multivariate model for the relative survival setting (17) , to examine the effect of prognostic factors: sex, period at diagnosis, histologic type, stage, age group and treatment. The excess hazard ratios (EHRs) of death within 5 years estimated by these models quantified the extent to which the risk of death in a given group differed from that in the reference category after considering the background risk of death in the general population (17, 18) . We estimated EHRs for males compared with females stratified by period at diagnosis, histologic type, stage, age group and treatment by controlling for other factors. In addition, we included the interaction variables between sex and period at diagnosis to examine trends in sex differences in excess hazard of death from cancer. Data management and statistical analyses were conducted using Stata version 13 (STATA Corporation, College Station, TX, USA).
Histologic type and stage at diagnosis of some cases were missing (16.6% and 11.7%, respectively) (Supplementary Table S1 ). We assumed the mechanism of missingness for histologic type and stage was missing at random (MAR) and applied the multiple imputation (MI) approach to solve this problem (19) . For each incomplete variable (histologic type and stage), we used the multinomial logistic regression model including another incomplete variable, complete variables (follow-up time, vital status (patients are alive or dead), sex, age at diagnosis, period at diagnosis and treatment) and interactions between follow-up time and other variables. In the MI approach, we obtained 10 complete data sets containing the imputed values of histologic type and stage for cases with missing information. We applied Rubin's rules to estimate relative survival, EHRs and standard errors combining the 10 complete data sets.
Results
The proportion of ADC among lung cancer patients in Osaka increased between 1975 and 2007 from 60.3% to 70.9% in females and from 36.2% to 44.6% in males. The proportion of localized cancer increased from 17.3% to 28.1% for females but increased very little for males ( Table 1) .
The 5-year relative survival between 1975 and 2007 increased and the difference between sexes became larger (from 6.0% (95% CI: 4.9-7.3%) to 30.9% (95% CI: 29.6-32.2%) in females and from 7.2% (95% CI: 6.5-8.0%) to 19.6% (95% CI: 18.9-20.3%) in males) ( Table 2 , Supplementary Fig. S1 ). Sex differences in the 5-year relative survival of patients with ADC and aged 15-64 years increased while that of localized cancer increased a little ( Table 2 , Supplementary Fig. S2 and Fig. S3 ). Table 3 shows results from the univariate and multivariate excess hazard model. Males have a higher risk of death from lung cancer than females after adjusting for period at diagnosis, histologic type, stage, age group and treatment (surgery, radiotherapy and chemotherapy) (EHR: 1.19; 95% CI: 1.16-1.21). Favorable prognostic factors were identified as follows: recent period at diagnosis, ADC, earlier stage, younger age group and surgery/radiotherapy/ chemotherapy performed.
According to the stratified multivariate analysis by period at diagnosis, histologic type, stage, age group and treatment (Supplementary Table S2 ), males with ADC had a higher risk of death than females (EHR: 1.27; 95% CI: 1.24-1.31) while a significant difference between sexes was not observed in SQC. Females had a significantly better prognosis than males irrespective of stage, Table 1 . Characteristics of lung cancer patients in Osaka, Japan stratified by sex, period at diagnosis, histological type, stage, age group and treatment 1975-1980 1981-1986 1987-1992 1993-1997 1998-2002 2003-2007 Supplementary Table S3 ), the improvement in excess hazard of death within 5 years was larger in females after adjustment for all covariates (Fig. 1) . In the interaction model 2 in Supplementary Table S3 , which does not include histologic type and stage at diagnosis, the EHRs for the interaction between sex and period at diagnosis were larger than those of the interaction model 1.
Discussion
Sex differences in lung cancer survival have become larger, especially in ADC and since the late 1990s. An increase in the proportions of ADC and localized cancer, especially in females, might be the reason for the widening sex differences in lung cancer survival because the prognosis for ADC and localized cancer is statistically significantly better than that for other histologic types and stages in our study (Table 3, Supplementary Table S3 ). Although sex differences are observed in the proportions of histologic type and stage, female sex was an independent favorable prognostic factor after adjustment for other covariates in the multivariate model: period at diagnosis, stage, age group and treatment and belonging to specific histologic type.
Possible factors which may influence sex differences in lung cancer survival
Smoking is the largest population attributable risk for cancer death (20, 21) . In addition, it relates to poor survival for lung cancer patients (22) . The differences in smoking prevalence between sexes can be related to the sex difference of lung cancer survival because smoking prevalence in Japan is higher among males than females (smoking prevalence in Japan in 2012: 31.5% for males and 14.3% for females) ( Supplementary Fig. S4 ) (23) . While smokers tend to have SQC and SMC (24), never smokers are more likely to have well differentiated ADC (25) . The sex differences in survival have become wider, although those in smoking prevalence have become smaller (Supplementary Fig. S2 and Fig. S4 ). It is possible that the influence of other factors on the widening gaps in survival is larger than that of smoking prevalence. We need to examine trends of sex differences in smoking prevalence and lung cancer survival with further studies. The introduction and widespread use of CT scanning might have contributed to the sex differences in lung cancer survival. Low-dose CT was introduced as a diagnostic technique in Japan in the 1990s. Helical CT scanning is more likely to detect early stage peripherally located ADC than conventional screenings such as chest X-ray and could lead to substantial increases in surgical resection and better prognosis from the 1990s onwards (26, 27) . The attendance rate at lung cancer screening using CT scanning in Osaka is noticeably low (no more than 10%) and sex differences have not been observed (28) . However, CT scanning has been widely used in other clinical settings to assess symptoms, such as chest pain, hemosputum and faint abnormal shadow in chest X-ray. Since females smoke less and are more likely to have ADC than males (12, 23, 29) , the influence of CT scanning on survival could be larger in females than males. This is partly explained by the increase in the incidence of ADC and the substantial increase in the survival of patients with ADC, localized cancer and surgery, especially in females since the 1990s in Osaka ( Table 2 , Supplementary Fig. S2 and Fig. S3) (30-32) .
The different distribution of EGFR mutations between sexes might have contributed to prognostic advantages in lung cancer survival for females. This is because tyrosine kinase inhibitors such as gefitinib contribute to improvements in the prognosis of ADC patients with EGFR mutations and ADC and these mutations are more frequent in females than males (33) (34) (35) . Since gefitinib was approved in 2002 in Japan (34) , it is likely that this drug has partly contributed to the increasing sex differences in lung cancer survival since the 2000s.
The survival advantage among females was the most prominent in ADC of all histologic types (Supplementary Table S2 and Fig. S2 ), which accords with population-based and cohort studies in other countries (10, 36) . Several clinical-based studies reported significantly better survival in females than in males in ADC after surgical resection or cisplatin-based chemotherapy (8, 37, 38) . The advantage of females especially in ADC can be explained by the widespread use of CT scanning and tyrosine kinase inhibitors, as we mentioned above.
Comparison with other studies
Our studies showed that sex differences in lung cancer survival in Osaka have become larger, especially since the late 1990s, after adjustment for covariates. We need to be cautious about the representativeness of Osaka data to the whole Japanese population. Fiveyear relative survival in Osaka has been lower than that in Japan for both sexes and sex differences in the 5-year relative survival in Osaka have been smaller than those in Japan (2). Smoking prevalence for males in Osaka is almost the same as for Japan as a whole, while among females it is a little higher in Osaka (Osaka: 15.7% in 2001 and 12.3% in 2010; Japan as a whole: 14.0% in 2001 and 10.4% in 2010) (39) . The smaller sex differences in survival in Osaka than Japan may be due to the higher smoking prevalence in females in Osaka if smoking behaviors affect lung cancer survival.
In a population-based study in Norway between 1988 and 2007, sex differences in lung cancer survival, which were not adjusted for any variables, were much smaller than those in Osaka and have slightly increased or levelled off ( Supplementary Fig. S1 ) (10) . One reason for this may be the smaller difference in the proportions of ADC and localized cancer between sexes in Norway than in Osaka. In USA, sex differences in lung cancer survival are smaller than Osaka and almost levelled off between 1975 and 2007 (40) . These results can be explained by the smaller difference in smoking prevalence between sexes in these two countries than in Osaka (smoking prevalence in 2012: 16.2% for males and 17.2% for females in Norway; 17.2% for males and 14.3% for females in USA) (41) . The higher frequency of EGFR mutations in East Asian females than other ethnicities might also have contributed to the larger sex differences in Japan (33) .
We showed that sex, period at diagnosis, histologic type, stage, age and treatment are independent prognostic factors for lung cancer, which is almost the same as the results of other clinical-based studies and population-based studies (8) (9) (10) (11) (12) . However, we observed that ADC had statistically significantly better prognosis than SQC, which is different from the results of these previous studies (8) (9) (10) (11) (12) . Kawaguchi et al. reported that ADC had significantly better survival than SQC among ever-smokers (42) . We need further studies to investigate the effect of histologic types on lung cancer.
Limitations
Some data from the OCR did not include information about histologic type and stage, especially in earlier periods (Supplementary  Table S1 ). Although we applied the MI approach to solve this problem assuming that the mechanism of missingness for histologic type and stage was MAR, where the chance of data being missing is independent of unseen values. However, it is usually difficult to confirm the mechanism of the missingness.
In our analysis, we excluded DCO cases, following the international standard method. The percentage of DCO of lung cancer in the OCR has decreased over the observed periods (21.9% in 1975-1980, 22.0% in 1981-1986, 24.1% in 1987-1992, 19.4% in 1993-1997, 18.5% in 1998-2002 and 15.8% in 2003-2007) . Excluding DCO cases might have overestimated relative survival of lung cancer, and influenced trends in survival.
The OCR did not collect information about smoking habits, performance status, socioeconomic status, modality of detection, or EGFR mutations of patients. Therefore, we could not determine the impact of widespread use of CT scanning and use of tyrosine kinase inhibitors on lung cancer survival directly. To consider these factors directly, we need to establish a linkage system between the hospital episode, health insurance claims for the diagnosis and treatment, smoking habits, and socioeconomic status, to understand the mechanism of sex differences in lung cancer survival.
Future recommendations
The relationship between smoking prevalence and histologic type or stage is unclear. However, the lower smoking prevalence in females than in males may be related to the higher proportion of ADC in females, which could result in better prognosis in females. Therefore, a decrease in smoking prevalence in males may contribute to an improvement in their lung cancer survival.
In order to reduce the gap between sexes in lung cancer survival, further studies are needed to identify the mechanism of the gap. We need to explore the causal relationship between sex and lung cancer survival by explaining potential confounding variables such as histologic type, stage at diagnosis, screening uptake, smoking habits, gene mutations, socioeconomic status and unknown other factors.
Conclusion
In conclusion, using large-size population-based cancer registry data, we observed the long-term trends in sex differences in lung cancer survival in Osaka, Japan. Our studies are the first to analyze the trends of sex differences in lung cancer survival in Japan by histologic type or other variables over the long-term periods. The sex differences in lung cancer survival have become wider, especially in ADC and since the late 1990s. This can be partly explained by the sex differences in the proportions of histologic type and stage. To reduce the gap in lung cancer survival between sexes, further investigation is needed to understand the impact of sex on each variable.
Supplementary data
Supplementary data are available at Japanese Journal of Clinical Oncology online.
